Eteplirsen success in Study 202 for Duchenne Muscular Dystrophy-Sarepta Therapeutics

Sarepta Therapeutics, announced data through Week 120 from Study 202, a Phase IIb open-label extension study of eteplirsen in patients with Duchenne Muscular Dystrophy (DMD). Results through more than two years showed a continued stabilization of walking ability in eteplirsen-treated patients evaluable on the 6-minute walk test (6MWT). As previously reported, Study 202 met its primary endpoint of increased novel dystrophin as assessed by muscle biopsy at Week 48 and is now in the long-term extension phase in which patients continue to be followed for safety and clinical outcomes.